Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer.

Anbenitamab plus HB1801 significantly improved 24-month progression-free survival versus THP in 885 Chinese patients with HER2-positive advanced breast cancer (58.5% vs 34.4%).

• Why it matters: THP is established first-line therapy, but the efficacy and safety of anbenitamab plus albumin-bound docetaxel in this setting were unknown.
• What they did: In a phase 3, multicenter, open-label randomized trial in China, patients received anbenitamab plus HB1801 or THP; progression-free survival was assessed by blinded independent central review.
• The result: At interim analysis (401 events; median follow-up 21.0 months), the hazard ratio for progression or death was 0.46 (95% CI 0.37 to 0.56; P<0.001), with higher objective response (87.6% vs 73.4%) and more grade 3+ adverse events (45.9% vs 34.4%).